Reported 1 day ago
Amgen is set to begin its phase 3 trial for MariTide, a monthly weight-loss drug, addressing previous investor concerns about safety and dosing. The trial will feature a three-step dose escalation, starting at 21 mg and culminating at 350 mg. Despite enthusiasm from some analysts regarding the drug's potential and its appeal for patients, investors remain skeptical due to competing products and relatively modest weight loss results compared to market leaders. The approval of MariTide could lead it to be the first monthly injectable weight-loss medication if successful.
Source: YAHOO